Pluri (PLUR) Net Cash Flow (2010 - 2025)
Pluri (PLUR) posted quarterly Net Cash Flow of -$2.5 million for Q4 2025, down 163.41% year-over-year from $4.0 million in Q4 2024, and down 61.41% quarter-over-quarter from -$1.6 million in Q3 2025.
Pluri (PLUR) Net Cash Flow (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Net Cash Flow for 16 consecutive years, with -$2.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Cash Flow fell 163.41% year-over-year to -$2.5 million; the TTM figure through Dec 2025 stood at -$15.3 million (down 114.83% YoY), while the FY2025 annual figure was -$652000.0, down 146.44% from the prior year.
- Net Cash Flow declined to -$2.5 million in Q4 2025 per PLUR's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $19.6 million in Q2 2021 and bottomed at -$16.0 million in Q3 2021.
- Historically, Net Cash Flow has averaged -$1.7 million across 5 years, with a median of -$1.7 million in 2022.
- On a YoY basis, Net Cash Flow climbed as much as 1387.78% in 2024 and fell as far as 6225.45% in 2024.
- Pluri's Net Cash Flow stood at $4.5 million in 2021, then plunged by 226.03% to -$5.6 million in 2022, then jumped by 104.81% to $270000.0 in 2023, then jumped by 1387.78% to $4.0 million in 2024, then sank by 163.41% to -$2.5 million in 2025.
- Business Quant data shows PLUR's Net Cash Flow at -$2.5 million in Q4 2025, -$1.6 million in Q3 2025, and -$2.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | -2.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.55 Mn |
| Dec 31, 2025 | -2.55 Mn |
| Sep 30, 2025 | -1.58 Mn |
| Sep 30, 2025 | -1.58 Mn |
| Jun 30, 2025 | -2.62 Mn |
| Jun 30, 2025 | -2.62 Mn |
| Mar 31, 2025 | -8.54 Mn |
| Mar 31, 2025 | -8.54 Mn |
| Dec 31, 2024 | 4.02 Mn |
| Dec 31, 2024 | 4.02 Mn |
| Sep 30, 2024 | -3.48 Mn |
| Sep 30, 2024 | -3.48 Mn |
| Jun 30, 2024 | -9.12 Mn |
| Jun 30, 2024 | -9.12 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Dec 31, 2023 | 270,000.00 |
| Dec 31, 2023 | 270,000.00 |
| Sep 30, 2023 | -55,000.00 |
| Sep 30, 2023 | -55,000.00 |